Combined RNA/tissue profiling identifies novel Cancer/testis genes.

Area of Science:

• Genomics
• Oncology
• Molecular Biology

Background:

• Cancer/Testis (CT) genes are expressed in germ cells, silenced in normal tissues, and reactivated in tumors, influencing cancer progression.
• Identifying CT genes is crucial for cancer diagnostics and therapeutics but is hindered by diverse data sources and methodologies.
• Standardized data acquisition and analysis are essential for reliable CT gene discovery.

Purpose of the Study:

• To identify novel Cancer/Testis (CT) genes using integrated multi-omics data.
• To explore the potential of identified CT genes as cancer biomarkers and therapeutic targets.
• To address the challenges in detecting CT gene expression across various tissue types.

Main Methods:

• GeneChip-based RNA profiling of testis, germ cells, somatic cancers, and normal somatic tissues.
• Integration of data from Expression Project for Oncology and Gene Omnibus Repository.
• Protein level validation using cancer tissue microarrays and publicly available data (Human Protein Atlas).

Main Results:

• Identification of 478 candidate loci, including known CT genes, oncogenic genes, and novel candidates.
• Validation of RNA expression data at the protein level for specific genes (SPESP5, GALNTL5, PDCL2, C11orf42).
• Demonstration of combined RNA/tissue profiling's utility in discovering clinically relevant CT genes.

Conclusions:

• Combined RNA and protein profiling effectively identifies novel Cancer/Testis (CT) genes with potential clinical applications.
• The identified CT genes may serve as valuable biomarkers or therapeutic targets in oncology.
• Challenges remain in accurately detecting CT gene expression in heterogeneous biological samples.